EUVIMEDEUVIMED entdecken
Crossref

CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors

Nikhil Sekar, Songzhu Zhao, Alexander Rudich, Natalie Johns, Jennifer D Hwang, Po-Lan Su, Jian Hu, Daniel Spakowicz, Lai Wei, Yuanquan Yang, Ting-Yuan David Cheng, Christopher Coss und 15 weitere

Journal of the National Comprehensive Cancer Network · 31.03.2026 · 24 (3.5)

DOI: 10.6004/jnccn.2025.7467 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of the National Comprehensive Cancer Network, erschienen am 31.03.2026. Verfasst von Nikhil Sekar und 26 weiteren Autor:innen. Beteiligte Einrichtung: 1The Ohio State University College of Medicine, Columbus, OH.

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Kein Abstract verfügbar.

Autor:innen und Institutionen

  • 1The Ohio State University College of Medicine, Columbus, OH.
  • 2The Center for Biostatistics, The Ohio State University College of Medicine, Columbus, OH.
  • 3Division of Medical Oncology, The Ohio State University Comprehensive Cancer Center, Columbus, OH.
  • 4National Cheng Kung University Hospital, Tainan, Taiwan.
  • 5Division of Hospital Medicine, The Ohio State University Wexner Medical Center, Columbus, OH.
  • 6Division of Cancer Prevention and Control, Department of Internal Medicine, The Ohio State University College of Medicine, Columbus, OH.

Zitieren

APA

Sekar, N., Zhao, S., Rudich, A., Johns, N., Hwang, J. D., Su, P. L., Hu, J., Spakowicz, D., Wei, L., Yang, Y., Cheng, T. D., Coss, C., Phelps, M., Parang, B., Gheeya, J., Roof, L., Alahmadi, A., Memmott, R., Kaufman, J., …, & Li, M. (2026). CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors. Journal of the National Comprehensive Cancer Network, 24(3.5). https://doi.org/10.6004/jnccn.2025.7467

Vancouver

Sekar N, Zhao S, Rudich A, Johns N, Hwang JD, Su PL, et al. CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors. Journal of the National Comprehensive Cancer Network. 2026;24(3.5). doi:10.6004/jnccn.2025.7467

BibTeX
@article{Sekar2026,
  author = {Sekar, Nikhil and Zhao, Songzhu and Rudich, Alexander and Johns, Natalie and Hwang, Jennifer D and Su, Po-Lan and Hu, Jian and Spakowicz, Daniel and Wei, Lai and Yang, Yuanquan and Cheng, Ting-Yuan David and Coss, Christopher and Phelps, Mitch and Parang, Bobak and Gheeya, Jinesh and Roof, Logan and Alahmadi, Asrar and Memmott, Regan and Kaufman, Jacob and Presley, Carolyn and He, Kai and Burns, Timothy and Shields, Peter and Rolfo, Christian and Carbone, David and Owen, Dwight and Li, Mingjia},
  title = {CLO26-084: Prognostic Value of Sarcopenia in Patients With Metastatic NSCLC Receiving First-Line Immune Checkpoint Inhibitors},
  journal = {Journal of the National Comprehensive Cancer Network},
  year = {2026},
  volume = {24},
  number = {3.5},
  doi = {10.6004/jnccn.2025.7467}
}
Kostenlos starten →